Technology News and Research

RSS

Discovery of novel gene profile that may identify colon stem cells

Researchers at Jefferson Medical College have uncovered a novel pattern of gene expression in the stem cell-rich bottom of tiny “crypts” in the tissue lining the colon. By identifying these patterns, the scientists hope to be able to identify mechanisms through which stem cells contribute to the development of colon cancer.

30 Mar 2004

Human Genome Sciences can begin cardiovascular disease research

Human Genome Sciences, Inc.announced today that it has received a clinical development milestone payment from its partner, GlaxoSmithKline, related to the initiation of Phase 1 clinical trials of 677116 for the treatment of cardiovascular disease. 677116 is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques.

30 Mar 2004

Extraction of RNA from Archived Formalin-Fixed, Paraffin-Embedded Tissue

For the first time, Fox Chase Cancer Center researchers have demonstrated the ability to extract RNA from formalin-fixed, paraffin-embedded tissue samples archived for up to five years. What's more, the technology used retrieves high-quality samples, allowing researchers to identify cancer-related genetic changes. Accepted as a "late-breaking" abstract, the research was presented today at the 95th Annual Meeting of the American Association for Cancer Research by Renata Coudry, M.D., a research pathologist at Fox Chase Cancer Center.

30 Mar 2004

New storage method amplifies cells available for science

Like many other kinds of cells used in biomedical research, human embryonic stem cells are stored and transported in a cryopreserved state, frozen to -320 degrees Fahrenheit, the temperature of their liquid nitrogen storage bath. But when scientists thaw the cells for use in the lab, less than 1 percent awake from their frigid slumber and assume their undifferentiated state. This 'blank slate' form is characteristic of stem cells and essential for the basic science required before the promising cells are ready for the clinic.

30 Mar 2004

Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors

Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research demonstrated highlighted how some drugs may one day offer previously unforeseen benefits for patients.

30 Mar 2004

Emerging technologies in tissue engineering and regenerative medicine analysis

Pathbreaking developments in tissue engineering and regenerative therapies are facilitating the design and growth of new organs in labs using biopolymer scaffolds and matrices. Analysis of potential markets for tissue engineering reveals that basic problems such as vascularity must be solved before such implants can gain acceptance as standard treatment methods.

30 Mar 2004

Genencor Sells Its Therapeutic Vaccine Program to Innogenetics

Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innogenetics will develop and commercialize current product candidates in Genencor’s vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.

30 Mar 2004

First North American sales of Raycell X-ray blood irradiator

The Indiana Blood Center in Indianapolis, Indiana, and SMDC Laboratory in Duluth, Minnesota have both chosen to purchase MDS Nordion's Raycell(TM) blood irradiator as a means of eliminating delays in receiving irradiated blood and blood products from external suppliers and improving the service they provide to physicians and patients.

30 Mar 2004

Trial of new drug that may halt progression of Type I Diabetes

The results of a long-term clinical trial on a new drug designed to inhibit the progression of type I diabetes was announced at the International Diabetes Society meeting in Cambridge, England, March 29. The findings of the 18-month long clinical trial confirm the drug's efficacy in improving a diabetic's ability to produce insulin.

30 Mar 2004

Researchers tap modified plant viruses to ward off cervical cancer-causing infections

New vaccinations to prevent infections that lead to cervical cancer and targeted therapeutics aimed at breast cancer were examples of research highlights presented by scientists today at the 95th Annual Meeting of the American Association for Cancer Research. Scientists described advances that feed into the drug development 'pipeline,' and show strong promise for controlling existing tumors or addressing the pathogen that causes tumors.

29 Mar 2004

Novel vaccine technology to suppress the growth of certain tumors

MedImmune, Inc. and Cerus Corporation have announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors.

From Baxter International Inc. 29 Mar 2004

Three of the world’s top women chemists visit UK to inspire young scientists

Three of the world’s top women chemists are visiting the UK this week (29 March - 2 April) to tour institutions and talk about their research with the aim of inspiring young scientists to emulate their achievements. The inaugural Rosalind Franklin International Lectureship Programme has been masterminded by Professor Susan Gibson, Imperial College London, who funded the initiative with her prize money from the Royal Society Rosalind Franklin Award.

29 Mar 2004

Australia’s first large-scale study into genetic discrimination

The survey of people who have had a predictive genetic test for various inherited conditions aims to investigate the advantages and disadvantages of genetic test information on people’s lives and to examine cases of alleged discrimination.

28 Mar 2004

Obesity research targeting 3 to 5 year olds

A ground-breaking study at the University of Wollongong, Australia is targeting factors affecting the development of obesity in young pre-school children aged between three and five.

28 Mar 2004

$Study demonstrates pharmacists ability to identify & refer patients at-risk for fractures$

Study demonstrates pharmacists ability to identify & refer patients at-risk for fractures

Results from Project ImPACT: Osteoporosis were discussed today during the Annual Meeting of the American Pharmacists Association. Published in the March/April 2004 issue of the Journal of the American Pharmacists Association the authors, Jean-Venable “Kelly” Goode, Kim Swiger, and Benjamin M. Bluml, suggest that when patients, pharmacists and physicians collaborate closely, using pharmacy-based testing to identify and refer patients who are at-risk for future fracture that breakthrough results are possible.

28 Mar 2004

New patent to develop antibody therapies for cancer and other diseases

The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.

26 Mar 2004

A simple blood test could determine whether older women with diabetes would benefit from, or be harmed by, vitamin doses designed to protect their ailing hearts

A simple blood test could determine whether older women with diabetes would benefit from, or be harmed by, vitamin doses designed to protect their ailing hearts, according to researchers at the Technion-Israel Institute of Technology.

26 Mar 2004

Oral medication for diabetes a step closer

University of Toronto researchers have shown that "designer molecules" can interact with the body's insulin receptor, a step toward the development of an oral medication for diabetes. U of T professors Lakshmi Kotra, Cecil Yip, Peter Ottensmeyer and Robert Batey have created the first small molecules using the three-dimensional structure of the insulin receptor. A receptor is the site on the surface of a cell to which molecules with specific tasks, such as hormones, attach themselves. Insulin's task is to initiate the utilization of sugar in the blood.

26 Mar 2004

Joint Research Collaboration to Predict 3-D Protein Structures and Support Drug Discovery

IBM today announced that the University at Buffalo (UB) Center of Excellence in Bioinformatics, The State University of New York, will use IBM technologies and research expertise to study the structure and behavior of human proteins. The outcome of this research could lead to more targeted drugs to treat diseases such as cancer, Alzheimer's, AIDS and multiple sclerosis.

25 Mar 2004

New Research Information on Tumor Necrosis Therapy

Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute’s Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People’s Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.

25 Mar 2004